Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Feb 4 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and ...

Atopic dermatitis, also known as atopic eczema, is a long-term skin condition ... Sanofi to increase competition in atopic dermatitis market after Dupixent’s success - (https://www.globaldata ...

Sales were also boosted by demand for the anti-inflammatory drug Dupixent, a treatment for eczema, asthma and, more recently, chronic obstructive pulmonary disease, among other indications.